In the recent past, our growth has been propelled by consistent expansion in the global generics market. This was enabled through an aggressive programme targeting three strategic platforms for launching generic products in the advanced markets.

These comprise:

  • Injectables ((Cephalosporins & Non-Cephalosporins)
  • Blockbuster molecules going off patent
  • Value-added generics (NDDS, niche)

We have also developed products for Abbreviated New Drug Applications (ANDAs), for the US and European markets. Our product pipeline focuses on less competitive and difficult to replicate products.

There are 87 ANDAs approved in the US and 23 in the EU markets. We continue to have a rich pipeline of ANDAs.